Guardant Health (GH) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended September 2024, Guardant Health (GH) reported revenue of $191.48 million, up 33.9% over the same period last year. EPS came in at -$0.45, compared to -$0.73 in the year-ago quarter.The reported revenue represents a surprise of +12.72% over the Zacks Consensus Estimate of $169.87 million. With the consensus EPS estimate being -$0.55, the EPS surprise was +18.18%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Guardant Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Total tests performed (clinical & biopharmaceutical customers): 63,600 versus the three-analyst average estimate of 60,223. Revenue- Development services and other: $10.87 million versus $11.07 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +13.2% change. Revenue- Precision oncology testing: $180.60 million versus the five-analyst average estimate of $157.67 million. The reported number represents a year-over-year change of +35.4%. View all Key Company Metrics for Guardant Health here>>>Shares of Guardant Health have returned +11.7% over the past month versus the Zacks S&P 500 composite's +0.7% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Zacks Names #1 Semiconductor StockIt's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Guardant Health, Inc. (GH): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks